Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C23H34F3N5O7 |
| Molecular Weight | 549.5406 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)[C@H](NC(=O)CN1CCN(CC(O)=O)C1=O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](C(C)C)C(=O)C(F)(F)F
InChI
InChIKey=DHQQXRRWRZFGDW-WBAXXEDZSA-N
InChI=1S/C23H34F3N5O7/c1-12(2)17(19(35)23(24,25)26)28-20(36)14-6-5-7-31(14)21(37)18(13(3)4)27-15(32)10-29-8-9-30(22(29)38)11-16(33)34/h12-14,17-18H,5-11H2,1-4H3,(H,27,32)(H,28,36)(H,33,34)/t14-,17-,18-/m0/s1
| Molecular Formula | C23H34F3N5O7 |
| Molecular Weight | 549.5406 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 23:21:22 GMT 2025
by
admin
on
Mon Mar 31 23:21:22 GMT 2025
|
| Record UNII |
F7YC3C4YFS
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
F7YC3C4YFS
Created by
admin on Mon Mar 31 23:21:23 GMT 2025 , Edited by admin on Mon Mar 31 23:21:23 GMT 2025
|
PRIMARY | |||
|
9807572
Created by
admin on Mon Mar 31 23:21:23 GMT 2025 , Edited by admin on Mon Mar 31 23:21:23 GMT 2025
|
PRIMARY | |||
|
291778-77-3
Created by
admin on Mon Mar 31 23:21:23 GMT 2025 , Edited by admin on Mon Mar 31 23:21:23 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Infusion of AE-3763 dose-dependently prevented LPS-induced lung oedema and the infiltration of white blood cells into the hamster lung. AE-3763 also attenuated intratracheal HNE-induced hamster lung haemorrhage with ED50 values of 0.4 mg/kg/h and 1.3 mg/kg by intravenous infusion and intravenous bolus injection, respectively.
|
||
|
ACTIVE MOIETY |
Class: Imidazolines, Pyrrolidines; Mechanism of Action: Leucocyte elastase inhibitor; Highest Development Phase: Discontinued for Acute lung injury and Adult respiratory distress syndrome
|